

Nicolas Widmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1145227/publications.pdf>

Version: 2024-02-01

67
papers

3,132
citations

159358

30
h-index

155451

55
g-index

79
all docs

79
docs citations

79
times ranked

4073
citing authors

#	ARTICLE	IF	CITATIONS
1	Full-scale simulations to improve disaster preparedness in hospital pharmacies. BMC Health Services Research, 2022, 22, .	0.9	4
2	Swiss Armed Forces deployment during the COVID-19 pandemic: militia pharmacy officers' roles and duties. BMJ Military Health, 2021, 167, 141-141.	0.4	1
3	Emergency and Disaster Preparedness of European Hospital Pharmacists: A Survey. Disaster Medicine and Public Health Preparedness, 2021, 15, 25-33.	0.7	11
4	Using risk analysis to anticipate and mitigate failures during a hospital pharmacy relocation. European Journal of Hospital Pharmacy, 2021, 28, ejhpharm-2020-002525.	0.5	2
5	Using risk analysis to ensure patients' medication safety during hospital relocations and evacuations. European Journal of Hospital Pharmacy, 2021, 28, e171-e179.	0.5	0
6	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols, 2021, 10, e30090.	0.5	7
7	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	2
8	Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID -imatinib study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1497-1511.	1.3	8
9	Pharmaceutical Interventions on Hospital Discharge Prescriptions: Prospective Observational Study Highlighting Challenges for Community Pharmacists. Drugs - Real World Outcomes, 2021, , 1.	0.7	2
10	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	1.0	25
11	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in Pharmacology, 2020, 11, 177.	1.6	59
12	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	1.1	13
13	Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2020. 1157. 122160.	1.2	38
14	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 124-136.	1.2	31
15	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics, 2018, 57, 1-6.	1.6	29
16	Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 341-347.	1.4	22
17	Transition of care: A set of pharmaceutical interventions improves hospital discharge prescriptions from an internal medicine ward. European Journal of Internal Medicine, 2017, 38, 30-37.	1.0	18
18	Prescription of Sedative Drugs During Hospital Stay: A Swiss Prospective Study. Drugs - Real World Outcomes, 2017, 4, 225-234.	0.7	13

#	ARTICLE	IF	CITATIONS
19	Biases affecting injected doses of an experimental drug during clinical trials. <i>Trials</i> , 2016, 17, 321.	0.7	0
20	The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 5-13.	5.8	29
21	Erlotinib. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 2-21.	1.0	36
22	Therapeutic drug monitoring of targeted anticancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 887-893.	0.6	24
23	Representation of Medical Guidelines with a Computer Interpretable Model. <i>International Journal on Artificial Intelligence Tools</i> , 2014, 23, 1460003.	0.7	6
24	Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1307-1319.	1.1	60
25	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1090-1101.	1.1	50
26	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. <i>EMBO Molecular Medicine</i> , 2014, 6, 372-383.	3.3	311
27	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	1.3	31
28	Large-scale imatinib doseâ€“concentrationâ€“effect study in CML patients under routine care conditions. <i>Leukemia Research</i> , 2014, 38, 764-772.	0.4	37
29	Review of therapeutic drug monitoring of anticancer drugs part two â€“ Targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2020-2036.	1.3	248
30	Therapeutic drug monitoring in cancer â€“ Are we missing a trick?. <i>European Journal of Cancer</i> , 2014, 50, 2005-2009.	1.3	79
31	Review of therapeutic drug monitoring of anticancer drugs part 1 â€“ Cytotoxics. <i>European Journal of Cancer</i> , 2014, 50, 2010-2019.	1.3	205
32	OC014â€“Clinical Usefulness Of Therapeutic Concentration Monitoring For Imatinib Dosage Individualization: Results From The Randomized Controlled I-Come Trial. <i>Clinical Therapeutics</i> , 2013, 35, e6.	1.1	2
33	Personalized Drug Administrations Using Support Vector Machine. <i>BioNanoScience</i> , 2013, 3, 378-393.	1.5	2
34	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1007-1018.	1.1	33
35	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. <i>Clinical Pharmacokinetics</i> , 2013, 52, 9-22.	1.6	141
36	OC005â€“Biases On The Administered Parenteral Doses Of An Experimental Drug During Phase I Clinical Trials. <i>Clinical Therapeutics</i> , 2013, 35, e2-e3.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 150-167.	1.0	36
38	Long-term Prospective Population PK Study in GIST Patientsâ€”Letter. <i>Clinical Cancer Research</i> , 2013, 19, 949-949.	3.2	9
39	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 28-35.	0.9	86
40	Response to Calcagno Comment on â€œHigher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluidâ€. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, e14-e15.	0.9	1
41	A Drug Administration Decision Support System. , 2012, , .		6
42	Therapeutic Drug Monitoring of Imatinib. <i>Clinical Pharmacokinetics</i> , 2012, 51, 187-201.	1.6	43
43	An agenda for UK clinical pharmacology: Monitoring drug therapy. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 917-923.	1.1	27
44	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2
45	Example-based support vector machine for drug concentration analysis. , 2011, 2011, 153-7.		14
46	Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?. <i>Cancer Treatment Reviews</i> , 2011, 37, 291-299.	3.4	61
47	Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. <i>Lancet Oncology</i> , The, 2011, 12, 9-11.	5.1	22
48	12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 469-559.	1.0	7
49	Personalized modeling for drug concentration prediction using Support Vector Machine. , 2011, , .		4
50	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. <i>Blood</i> , 2011, 117, e75-e87.	0.6	202
51	Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 698-699.	0.4	5
52	Imatinib plasma levels: correlation with clinical benefit in GIST patients. <i>British Journal of Cancer</i> , 2010, 102, 1198-1199.	2.9	35
53	siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. <i>Drug Metabolism Letters</i> , 2010, 4, 114-119.	0.5	24
54	Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. <i>Clinical Pharmacokinetics</i> , 2010, 49, 741-765.	1.6	48

#	ARTICLE	IF	CITATIONS
55	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- <i>N</i> -Oxide, Anidulafungin, and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5303-5315.	1.4	108
56	Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1982-1996.	1.2	172
57	Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008, 43, 736-752.	0.7	52
58	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. <i>British Journal of Cancer</i> , 2008, 98, 1633-1640.	2.9	106
59	Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. <i>Leukemia</i> , 2007, 21, 1561-1562.	3.3	44
60	Reply to Zong et al.. <i>Leukemia</i> , 2007, 21, 1563-1564.	3.3	2
61	Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. <i>Journal of Hepatology</i> , 2006, 44, 167-175.	1.8	80
62	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 97-112.	1.1	161
63	Formulation Optimization in a University Hospital: The Example of Pediatric Solutions of the ACE Inhibitor Captopril. <i>Chimia</i> , 2005, 59, 357-358.	0.3	0
64	Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia. <i>Dermatology</i> , 2005, 211, 363-365.	0.9	44
65	Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 285-292.	1.2	52
66	Functional consequence of MDR1 expression on imatinib intracellular concentrations. <i>Blood</i> , 2003, 102, 1142-1142.	0.6	66
67	Setting-up a multi-center human research: Systematic observation during a Swiss clinical trial. <i>Bioethica Forum</i> , 0, , .	0.0	0